X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare AJANTA PHARMA with Glenmark Pharma - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AJANTA PHARMA vs GLENMARK PHARMA - Comparison Results

GLENMARK PHARMA 
   Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    AJANTA PHARMA GLENMARK PHARMA AJANTA PHARMA/
GLENMARK PHARMA
 
P/E (TTM) x 25.4 11.9 212.8% View Chart
P/BV x 10.5 3.2 332.2% View Chart
Dividend Yield % 0.6 0.4 149.6%  

Financials

 AJANTA PHARMA   GLENMARK PHARMA
EQUITY SHARE DATA
    AJANTA PHARMA
Mar-16
GLENMARK PHARMA
Mar-17
AJANTA PHARMA/
GLENMARK PHARMA
5-Yr Chart
Click to enlarge
High Rs1,720993 173.2%   
Low Rs1,103729 151.2%   
Sales per share (Unadj.) Rs194.6325.5 59.8%  
Earnings per share (Unadj.) Rs45.239.3 115.1%  
Cash flow per share (Unadj.) Rs50.348.7 103.4%  
Dividends per share (Unadj.) Rs8.002.00 400.0%  
Dividend yield (eoy) %0.60.2 244.0%  
Book value per share (Unadj.) Rs132.0159.2 82.9%  
Shares outstanding (eoy) m88.77282.17 31.5%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x7.32.6 274.2%   
Avg P/E ratio x31.221.9 142.4%  
P/CF ratio (eoy) x28.117.7 158.6%  
Price / Book Value ratio x10.75.4 197.7%  
Dividend payout %17.75.1 347.6%   
Avg Mkt Cap Rs m125,299242,991 51.6%   
No. of employees `000NA13.0 0.0%   
Total wages/salary Rs m2,57016,408 15.7%   
Avg. sales/employee Rs ThNM7,083.9-  
Avg. wages/employee Rs ThNM1,265.4-  
Avg. net profit/employee Rs ThNM855.1-  
INCOME DATA
Net Sales Rs m17,27591,857 18.8%  
Other income Rs m166374 44.5%   
Total revenues Rs m17,44292,230 18.9%   
Gross profit Rs m5,80720,367 28.5%  
Depreciation Rs m4512,644 17.0%   
Interest Rs m492,373 2.1%   
Profit before tax Rs m5,47415,724 34.8%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-810 0.0%   
Tax Rs m1,4603,827 38.1%   
Profit after tax Rs m4,01411,088 36.2%  
Gross profit margin %33.622.2 151.6%  
Effective tax rate %26.724.3 109.6%   
Net profit margin %23.212.1 192.5%  
BALANCE SHEET DATA
Current assets Rs m7,63968,746 11.1%   
Current liabilities Rs m2,71527,027 10.0%   
Net working cap to sales %28.545.4 62.8%  
Current ratio x2.82.5 110.6%  
Inventory Days Days4385 50.9%  
Debtors Days Days7996 82.3%  
Net fixed assets Rs m6,91424,132 28.6%   
Share capital Rs m177282 62.7%   
"Free" reserves Rs m11,44244,643 25.6%   
Net worth Rs m11,72144,925 26.1%   
Long term debt Rs m14945,363 0.3%   
Total assets Rs m14,814117,639 12.6%  
Interest coverage x112.97.6 1,481.1%   
Debt to equity ratio x01.0 1.3%  
Sales to assets ratio x1.20.8 149.3%   
Return on assets %27.411.4 239.7%  
Return on equity %34.224.7 138.8%  
Return on capital %46.519.1 243.0%  
Exports to sales %55.10-   
Imports to sales %6.00-   
Exports (fob) Rs m9,527NA-   
Imports (cif) Rs m1,038NA-   
Fx inflow Rs m10,42256,152 18.6%   
Fx outflow Rs m1,6788,084 20.8%   
Net fx Rs m8,74448,068 18.2%   
CASH FLOW
From Operations Rs m3,2646,574 49.6%  
From Investments Rs m-2,093-7,124 29.4%  
From Financial Activity Rs m-1,1865,432 -21.8%  
Net Cashflow Rs m-151,992 -0.7%  

Share Holding

Indian Promoters % 73.8 48.3 152.8%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 1.6 6.9 22.5%  
FIIs % 7.6 34.4 22.1%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.0 10.5 161.9%  
Shareholders   20,968 56,727 37.0%  
Pledged promoter(s) holding % 4.4 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare AJANTA PHARMA With:   TORRENT PHARMA  ALKEM LABORATORIES  DIVIS LABORATORIES  SANOFI INDIA  ALEMBIC PHARMA  

Compare AJANTA PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Global Stock Markets Rebound After Sharp Weekly Drop(RoundUp)

Global financial markets rallied this week and brushed aside a rise in global borrowing costs while the dollar hit its lowest level since 2014.

Related Views on News

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

Glenmark: Zetia Bolsters Sales and Profits (Quarterly Results Update - Detailed)

Oct 30, 2017

The 180-day exclusivity for Zetia enabled Glenmark to show strong growth in sales and profits during the quarter.

Glenmark Pharma: Lower Zetia Sales leads to Subdued Growth (Quarterly Results Update - Detailed)

May 18, 2017

Base price erosion in the US and lower Zetia sales impacts profits.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

More Views on News

Most Popular

Here's What You Should Do in this Market Crash(The 5 Minute Wrapup)

Feb 6, 2018

The market correction has provided a golden opportunity to buy five high-quality safe stocks.

As the Market Corrects... It's Time to Buy More(Smart Contrarian)

Feb 5, 2018

The recent sell off in the stock market offers buying opportunity in some quality small caps.

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

When Small is Not Always Beautiful(Chart Of The Day)

Feb 6, 2018

Big companies enjoying tax deductions and exemptions have an edge over the small companies.

What Should Mutual Fund Investors Do After LTCG Tax Norms(Outside View)

Feb 6, 2018

PersonalFN explain what investors should after LTCG tax norms.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

AJANTA PHARMA SHARE PRICE


Feb 16, 2018 (Close)

TRACK AJANTA PHARMA

  • Track your investment in AJANTA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

AJANTA PHARMA - NATCO PHARMA COMPARISON

COMPARE AJANTA PHARMA WITH

MARKET STATS